News & Events
- Seres Therapeutics to Present at the Stifel 2018 Healthcare Conference
- Seres Therapeutics Reports Third Quarter Financial Results and Provides Operational Updates
- Vedanta Biosciences Announces Preclinical Data on Microbiome-Derived Immuno-Oncology Candidate
- Seres Therapeutics to Host Third Quarter 2018 Financial Results and Operational Progress Conference Call and Webcast on November 8, 2018
- Seres Therapeutics Announces Appointment of Kevin Horgan, M.D., as Chief Medical Officer
- Vedanta Biosciences Announces Successful Phase 1a/1b Data Demonstrating Safety, Tolerability, and Proof of Mechanism for Lead, Rationally Defined Bacterial Consortium Product Candidate, VE303
- Seres Therapeutics to Present New Data Supporting SER-109 Clinical Activity at IDWeek 2018
- Vedanta Biosciences Appoints Susan Dillon, PhD, to Board of Directors
- Seres Therapeutics Strengthens Board of Directors with Appointment of Meryl Zausner, Experienced Biopharmaceutical Financial Leader
- The Microbiome Therapeutics Innovation Group Announces Coalition Formation and Leadership Team
- Seres Therapeutics Reports Second Quarter Financial Results and Provides Operational Updates
- Seres Therapeutics to Host Second Quarter 2018 Financial Results and Operational Progress Conference Call and Webcast on August 2, 2018
- Vedanta Biosciences Receives Award from the Crohn’s & Colitis Foundation to Advance a Microbiome-Derived Therapeutic Program for Interception and Treatment of Inflammatory Bowel Disease
- Microbiome Health Index™ Platform, Outcomes of Rebiotix’s RBX7455 Oral Formulation To Be Featured in Rapid Fire and Poster Sessions at ASM Microbe 2018
- Rebiotix Microbiota Restoration Therapy Products, Microbiome Health Index to Take Center Stage at Digestive Disease Week 2018